Conecte-se

Bibliografias temáticas / Daunorubicin

Índice

Artigos de revistas
Teses / dissertações
Livros
Capítulos de livros
Trabalhos de conferências

Literatura científica selecionada sobre o tema "Daunorubicin"

Autor: Grafiati

Publicado: 4 de junho de 2021

Última modificação: 29 de janeiro de 2023

Crie uma referência precisa em APA, MLA, Chicago, Harvard, e outros estilos

Selecione um tipo de fonte:

Consulte a lista de atuais artigos, livros, teses, anais de congressos e outras fontes científicas relevantes para o tema "Daunorubicin".

Ao lado de cada fonte na lista de referências, há um botão "Adicionar à bibliografia". Clique e geraremos automaticamente a citação bibliográfica do trabalho escolhido no estilo de citação de que você precisa: APA, MLA, Harvard, Chicago, Vancouver, etc.

Você também pode baixar o texto completo da publicação científica em formato .pdf e ler o resumo do trabalho online se estiver presente nos metadados.

Artigos de revistas sobre o assunto "Daunorubicin"

1

Drevin, Guillaume, Marie Briet, Caroline Bazzoli, Emmanuel Gyan, Aline Schmidt, Hervé Dombret, Corentin Orvain et al. "Daunorubicin and Its Active Metabolite Pharmacokinetic Profiles in Acute Myeloid Leukaemia Patients: A Pharmacokinetic Ancillary Study of the BIG-1 Trial". Pharmaceutics 14, n.º 4 (5 de abril de 2022): 792. http://dx.doi.org/10.3390/pharmaceutics14040792.

Texto completo da fonte

Resumo:

Daunorubicin pharmacokinetics (PK) are characterised by an important inter-individual variability, which raises questions about the optimal dose regimen in patients with acute myeloid leukaemia. The aim of the study is to assess the joint daunorubicin/daunorubicinol PK profile and to define an optimal population PK study design. Fourteen patients were enrolled in the PK ancillary study of the BIG-1 trial and 6–8 samples were taken up to 24 h after administration of the first dose of daunorubicin (90 mg/m2/day). Daunorubicin and daunorubicinol quantifications were assessed using a validated liquid chromatography technique coupled with a fluorescence detector method. Data were analysed using a non-compartmental approach and non-linear mixed effects modelling. Optimal sampling strategy was proposed using the R function PFIM. The median daunorubicin and daunorubicinol AUC0-tlast were 577 ng/mL·hr (Range: 375–1167) and 2200 ng/mL·hr (range: 933–4683), respectively. The median metabolic ratio was 0.32 (range: 0.1–0.44). Daunorubicin PK was best described by a three-compartment parent, two-compartment metabolite model, with a double first-order transformation of daunorubicin to metabolite. Body surface area and plasma creatinine had a significant impact on the daunorubicin and daunorubicinol PK. A practical optimal population design has been derived from this model with five sampling times per subject (0.5, 0.75, 2, 9, 24 h) and this can be used for a future population PK study.

Estilos ABNT, Harvard, Vancouver, APA, etc.

2

Zucchetti, Massimo, Amerigo Boiardi, Antonio Silvani, Idria Parisi, Stefano Piccolrovazzi e Maurizio D'Incalci. "Distribution of daunorubicin and daunorubicinol in human glioma tumors after administration of liposomal daunorubicin". Cancer Chemotherapy and Pharmacology 44, n.º 2 (17 de junho de 1999): 173–76. http://dx.doi.org/10.1007/s002800050964.

Texto completo da fonte

Estilos ABNT, Harvard, Vancouver, APA, etc.

3

&NA;. "Daunorubicin see Cytarabine/daunorubicin". Reactions Weekly &NA;, n.º 354 (junho de 1991): 8. http://dx.doi.org/10.2165/00128415-199103540-00027.

Texto completo da fonte

Estilos ABNT, Harvard, Vancouver, APA, etc.

4

Cusack, B. J., Stephan P. Young, Robert E. Vestal e Richard D. Olson. "Age-related pharmacokinetics of daunorubicin and daunorubicinol following intravenous bolus daunorubicin administration in the rat". Cancer Chemotherapy and Pharmacology 39, n.º 6 (28 de fevereiro de 1997): 505–12. http://dx.doi.org/10.1007/s002800050606.

Texto completo da fonte

Estilos ABNT, Harvard, Vancouver, APA, etc.

5

Choi, Min-Koo, Im-Sook Song, Dae-Duk Kim, Suk-Jae Chung e Chang-Koo Shim. "Altered Pharmacokinetics of Daunorubicin in Rats with CCl4-Induced Hepatic Injury". Journal of Pharmacy & Pharmaceutical Sciences 10, n.º 4 (16 de setembro de 2007): 443. http://dx.doi.org/10.18433/j3mw28.

Texto completo da fonte

Resumo:

PURPOSE. The effect of CCl4-induced experimental hepatic injury (CCl4-EHI) on the pharmacokinetics of daunorubicin was investigated systemically in rats, in an attempt to elucidate the major determinants of the effect of CCl4-EHI on the pharmacokinetics of the drug. METHODS. CCl4-EHI was induced in rats by a single intraperitoneal injection of CCl4 (1mL/kg rat), and a 24 h fasting period. Daunorubicin was administered intravenously to control and EHI rats at a dose of 11.3 mg/mL/kg and the in vivo pharmacokinetics was studied. The in vitro uptake of the drug into isolated hepatocytes and canalicular liver plasma membrane (cLPM) vesicles, as well as the liver microsomal degradation of the drug, were also determined. RESULTS. The area under the plasma concentration-time curve (AUC) of daunorubicin was increased by 1.6 times, resulting in a 34% decrease in the systemic clearance (CL) in rats with CCl4-EHI. The apparent biliary (CLbile) and urinary (CLurine) clearance of the drug were unchanged, whereas the AUC of daunorubicinol, the major metabolite of daunorubicin, was decreased by 66% in rats with CCl4-EHI. EHI seemed to affect the hepatobiliary elimination of the drug in several ways: the in vitro intrinsic sinusoidal uptake clearance was decreased by 20%; the in vitro intrinsic canalicular excretion clearance of the drug was increased by 1.7 times; and the in vitro liver microsomal degradation of daunorubicin was significantly retarded. CONCLUSIONS. CCl4-EHI appears to impair the hepatic metabolism of daunorubicin, thereby decreasing the CL and increasing the AUC of daunorubicin.

Estilos ABNT, Harvard, Vancouver, APA, etc.

6

Albrecht, K. W., S. Leenstra, P. J. M. Bakker, J. H. Beijnen, D. Troost, P. Kaaijk e D. A. Bosch. "High concentration of daunorubicin and daunorubicinol in human malignant astrocytomas after systemic administration of liposomal daunorubicin". Clinical Neurology and Neurosurgery 99 (julho de 1997): S231. http://dx.doi.org/10.1016/s0303-8467(97)82346-3.

Texto completo da fonte

Estilos ABNT, Harvard, Vancouver, APA, etc.

7

&NA;. "Daunorubicin". Reactions Weekly &NA;, n.º 1184 (janeiro de 2008): 15. http://dx.doi.org/10.2165/00128415-200811840-00044.

Texto completo da fonte

Estilos ABNT, Harvard, Vancouver, APA, etc.

8

&NA;. "Daunorubicin". Reactions Weekly &NA;, n.º 562 (agosto de 1995): 6. http://dx.doi.org/10.2165/00128415-199505620-00017.

Texto completo da fonte

Estilos ABNT, Harvard, Vancouver, APA, etc.

9

&NA;. "Daunorubicin". Reactions Weekly &NA;, n.º 392 (março de 1992): 5. http://dx.doi.org/10.2165/00128415-199203920-00013.

Texto completo da fonte

Estilos ABNT, Harvard, Vancouver, APA, etc.

10

&NA;. "Daunorubicin". Reactions Weekly &NA;, n.º 398 (abril de 1992): 6. http://dx.doi.org/10.2165/00128415-199203980-00014.

Texto completo da fonte

Estilos ABNT, Harvard, Vancouver, APA, etc.

Mais fontes

Teses / dissertações sobre o assunto "Daunorubicin"

1

Golightly, L. "Trypanosmoma brucei : Studies on the uptake and effects of daunorubicin and daunorubicin carrier preparations". Thesis, University of Sunderland, 1986. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.375648.

Texto completo da fonte

Estilos ABNT, Harvard, Vancouver, APA, etc.

2

Hardman, Mark Alan. "Design of potential antiprotozoal daunorubicin derivatives". Thesis, De Montfort University, 1985. http://hdl.handle.net/2086/10737.

Texto completo da fonte

Resumo:

Daunorubicin is an antitumour antibiotic which is highly active against the sleeping sickness parasite Trypanosoma rhodesiense in vitro, but which lacks in vivo activity. The object of this work was to modify daunorubicin so as to promote in vivo activity, and to study the mechanism by which daunorubicin is trypanocidal. A series of daunorubicin analogues, and derivatives in which daunorubicin was linked to a macromolecular carrier (known as daunorubicin conjugates) were prepared, and tested against trypanosome infected mice. Only daunorubicin conjugates in which drug was linked to the carrier by glutaraldehyde, were active. Treatment with these conjugates increased the survival time of infected mice from three days to as long as eleven days, and temporarily cleared parasites from the bloodstream of infected animals. Conjugates with other types of linkage were inactive. A fluorescence assay method was developed to measure drug release from conjugates. Investigation revealed that glutaraldehyde linked conjugate released about 20% of bound drug over a 2-3 hour period when incubated in murine plasma. In contrast, inactive conjugates either released bound drug very rapidly, or were stable to drug release. Daunorubicin is known to possess several potentially cytotoxic mechanisms of action, the most important being intercalation into the DNA double hel~x and stimulation of superoxide radical formation. In order to discover the contribution of these mechanisms to trypanocidal activity, the trypanocidal potency of a series of daunorubicin analogues was assessed in vitro. The ability of these analogues to intercalate into DNA and to stimulate lipid peroxidation and oxygen consumption was also assessed. The results were used to explore the relationship between these mechanisms and trypanocidal activity. These studies indicate that ability to bind to DNA is important in conferring trypanocidal activity on this group of antibiotics.

Estilos ABNT, Harvard, Vancouver, APA, etc.

3

Mohammed, Lina Yousif. "Studies on daunorubicin and actinorhodin type II polyketide synthases". Thesis, University of Bristol, 2018. https://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.761209.

Texto completo da fonte

Estilos ABNT, Harvard, Vancouver, APA, etc.

4

Wattana-Amorn, Pakorn. "Studies on the actinorhodin and daunorubicin type II polyketide synthases". Thesis, University of Bristol, 2007. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.441375.

Texto completo da fonte

Estilos ABNT, Harvard, Vancouver, APA, etc.

5

Bartels, Anna-Maria. "Durchflusszytometrische Untersuchungen zur zellulären Pharmakokinetik von freien und liposomal verkapseltem Daunorubicin". [S.l.] : [s.n.], 2002. http://deposit.ddb.de/cgi-bin/dokserv?idn=965428001.

Texto completo da fonte

Estilos ABNT, Harvard, Vancouver, APA, etc.

6

Maharaj, Vanitha. "A vibrational circular dichroism study of deoxyoctanucleotides and their daunorubicin complexes". Thesis, National Library of Canada = Bibliothèque nationale du Canada, 1997. http://www.collectionscanada.ca/obj/s4/f2/dsk3/ftp05/nq20751.pdf.

Texto completo da fonte

Estilos ABNT, Harvard, Vancouver, APA, etc.

7

Bartels, Anna-Maria. "Durchflußzytometrische Untersuchungen zur zellulären Pharmakokinetik von freien und liposomal verkapseltem Daunorubicin". Doctoral thesis, Humboldt-Universität zu Berlin, Medizinische Fakultät - Universitätsklinikum Charité, 2002. http://dx.doi.org/10.18452/14780.

Texto completo da fonte

Resumo:

In dieser Arbeit wurde die zelluläre Pharmakokinetik mit den Teilaspekten Invasion, Evasion und intrazellulärer Verteilung sowie die Apoptoseinduktion als Parameter der Pharmakodyna- mik von zwei Anthrazyklinen, dem freien und liposomal verkapseltem Daunorubicin unter- sucht. Die Versuche wurden anhand einer T-lymfatischen Zelllinie, den CEM-Zellen, durchgeführt. Mittels Durchflußzytometer und konfokaler Lasermikroskop wurde die intrazelluläre Fluoreszenz gemessen, die der intrazellulären Konzentration entsprach. Es zeigte sich, dass freies Daunorubicin anfangs deutlich schneller in die Zellen einströmte als liposomal verkapseltes Daunorubicin und früher die maximale Konzentration erreichte. Über eine längere Versuchszeit kam es aber zu einer Angleichung der maximal erreichten Konzen- trationen. Der Invasionsverlauf von Daunoxome verlief sigmoidförmig, während Daunorubi- cin einer Sättigungskinetik folgte. Der Invasionsverlauf beider Anthrazykline war sowohl zeit- als auch konzentrationsabhängig. Die Versuche zur intrazellulären Verteilung zeigten, dass sich beide Stoffe nach drei Stunden Inkubationszeit vom Zytoplasma in den Kern verteilten. Daunorubicin erreichte sehr schnell seine maximale Fluoreszenz im Kern. Bei Daunoxome ließ sich auch nach sechs Stunden Inkubation eine weitere Zunahme der Fluoreszenz messen. Die Untersuchungen zur Apoptoseinduktion unterstützten die Aussagen zur Invasion. Dauno- rubicin induzierte zu Anfang deutlich schneller Apoptose als Daunoxome. Über den gemessenen Versuchszeitraum kam es aber zu einer Angleichung aller Apoptoseraten. Auch hier zeigte sich eine Zeit- und Konzentrationsabhängigkeit. Die Ergebnisse der Evasionsversuche zeigten, dass Daunorubicin biphasisch und Daunoxome monophasisch ausströmte. Zusammenfassend kann gesagt werden, dass freies Daunorubicin initial eine bessere zelluläre Pharmakokinetik und damit eine höhere Zytotoxizität aufweist als liposomal verkapseltes Daunorubicin. Über die Zeit kommt es allerdings zu einer Angleichung der Zytotoxizität. Damit ist Daunoxome auf zellulärer Ebene mindestens genauso wirksam wie Daunorubicin.
We studied the cellular pharmacokinetics, including uptake, intracellular distribution and efflux, and the induction of apoptosis as a parameter of pharmacodynamics of the two anthracyclines, free and liposomal encapsulated daunorubicin. We used a flowcytometer and a confocal lasermicroscope to measure the intracellular fluorescence in CEM-cells, corresponding to the intracellular concentration of the drugs. Free daunorubicin invaded initially the cells much quicker than liposomal encapsulated daunorubicin and attained earlier the maximum concentration. After the examined time daunoxome achieved the same maximum concentration as daunorubicin. The invasion of liposomal encapsulated daunorubicin followed a sigmoid course, while free daunorubicin followed a saturation kinetic. It was shown that the uptake of both anthracyclines was time- and concentration-dependent. The examinations about the intracellular distribution showed, that both drugs accumulated in the nucleus after three hours of incubation. Daunorubicin attained quickly the maximum fluorescence there, while daunoxome increased slowly for the next six hours. The results of the apoptosis induction correlated to the results of the uptake experiments. Free daunorubicin induced initially quicker apoptosis than liposomal encapsulated daunorubicin. At the end of the measured time all the apoptosis rates of both drugs appeared to be equal. It was determined that the induction of apoptosis also is time- and concentration-dependent. The efflux of daunoxome was monophasic in contrast to a biphasic decline of daunorubicin. These results indicate that free daunorubicin has improved initial cellular pharmacokinetics and therefore enhanced cytotoxicity compared with liposomal encapsulated daunorubicin. But over the examined period both got equal cytotoxicity. Therefore daunoxome is on the cellular basis at least as effective as daunorubicin.

Estilos ABNT, Harvard, Vancouver, APA, etc.

8

Battisti, Robert F. "Modifying the sugar moieties of daunorubicin overcomes P-gp-mediated multidrug resistance". Connect to resource, 2007. http://hdl.handle.net/1811/25067.

Texto completo da fonte

Resumo:

Thesis (Honors)--Ohio State University, 2007.
Title from first page of PDF file. Document formatted into pages: contains 48 p.; also includes graphics. Includes bibliographical references (p. 46-48). Available online via Ohio State University's Knowledge Bank.

Estilos ABNT, Harvard, Vancouver, APA, etc.

9

Knaust, Eva. "Experimental studies on multidrug resistance in human leukaemia : role of cellular heterogeneity for daunorubicin kinetics /". Linköping : Dept. of Medicine and Care, Univ, 2005. http://www.bibl.liu.se/liupubl/disp/disp2005/med901s.pdf.

Texto completo da fonte

Estilos ABNT, Harvard, Vancouver, APA, etc.

10

Masquelier, Michèle. "Leukemia chemotherapy : experimental studies on pharmacological optimisation /". Stockholm, 2004. http://diss.kib.ki.se/2004/91-7140-046-X/.

Texto completo da fonte

Estilos ABNT, Harvard, Vancouver, APA, etc.

Mais fontes

Livros sobre o assunto "Daunorubicin"

1

Hardman, Mark Alan. Design of potential antiprotozoal daunorubicin derivatives. Leicester: Leicester Polytechnic, 1985.

Encontre o texto completo da fonte

Estilos ABNT, Harvard, Vancouver, APA, etc.

Capítulos de livros sobre o assunto "Daunorubicin"

1

Mader, Ines, Patrizia Fürst-Weger, Robert M. Mader, Elisabeth I. Semenitz, Robert Terkola e Sabine M. Wassertheurer. "Daunorubicin". In Paravasation von Zytostatika, 118–22. Vienna: Springer Vienna, 2002. http://dx.doi.org/10.1007/978-3-7091-3799-4_19.

Texto completo da fonte

Estilos ABNT, Harvard, Vancouver, APA, etc.

2

Mader, Ines, Patrizia Fürst-Weger, Robert Mader, Elisabeth Nogler-Semenitz e Sabine Wassertheurer. "Daunorubicin". In Extravasation of Cytotoxic Agents, 175–82. Vienna: Springer Vienna, 2010. http://dx.doi.org/10.1007/978-3-211-88893-3_26.

Texto completo da fonte

Estilos ABNT, Harvard, Vancouver, APA, etc.

3

Mader, Ines, Patrizia E. Fürst-Weger, Robert M. Mader, Elisabeth I. Semenitz, Robert Terkola e Sabine M. Wassertheurer. "Daunorubicin". In Extravasation of Cytotoxic Agents, 107–11. Vienna: Springer Vienna, 2003. http://dx.doi.org/10.1007/978-3-7091-3710-9_19.

Texto completo da fonte

Estilos ABNT, Harvard, Vancouver, APA, etc.

4

Mader, Ines, Patrizia Fürst-Weger, Robert M. Mader, Elisabeth I. Semenitz, Robert Terkola e Sabine M. Wassertheurer. "Daunorubicin liposomal". In Paravasation von Zytostatika, 123–26. Vienna: Springer Vienna, 2002. http://dx.doi.org/10.1007/978-3-7091-3799-4_20.

Texto completo da fonte

Estilos ABNT, Harvard, Vancouver, APA, etc.

5

Mader, Ines, Patrizia Fürst-Weger, Robert Mader, Elisabeth Nogler-Semenitz e Sabine Wassertheurer. "Daunorubicin liposomal". In Extravasation of Cytotoxic Agents, 183–86. Vienna: Springer Vienna, 2010. http://dx.doi.org/10.1007/978-3-211-88893-3_27.

Texto completo da fonte

Estilos ABNT, Harvard, Vancouver, APA, etc.

6

Mader, Ines, Patrizia E. Fürst-Weger, Robert M. Mader, Elisabeth I. Semenitz, Robert Terkola e Sabine M. Wassertheurer. "Daunorubicin liposomal". In Extravasation of Cytotoxic Agents, 112–15. Vienna: Springer Vienna, 2003. http://dx.doi.org/10.1007/978-3-7091-3710-9_20.

Texto completo da fonte

Estilos ABNT, Harvard, Vancouver, APA, etc.

7

Chaires, Jonathan B. "Molecular Recognition of DNA by Daunorubicin". In ACS Symposium Series, 156–67. Washington, DC: American Chemical Society, 1994. http://dx.doi.org/10.1021/bk-1995-0574.ch010.

Texto completo da fonte

Estilos ABNT, Harvard, Vancouver, APA, etc.

8

Shrestha, Biplav, Anaya Raj Pokhrel, Sumangala Darsandhari, Prakash Parajuli, Jae Kyung Sohng e Ramesh Prasad Pandey. "Engineering Streptomyces peucetius for Doxorubicin and Daunorubicin Biosynthesis". In Environmental Chemistry for a Sustainable World, 191–209. Cham: Springer International Publishing, 2019. http://dx.doi.org/10.1007/978-3-030-01881-8_7.

Texto completo da fonte

Estilos ABNT, Harvard, Vancouver, APA, etc.

9

Knaust, E., A. Gruber, A. Porwit-MacDonald e C. Peterson. "Functional Studies of Daunorubicin Transport in Human Leukemic Cells". In Haematology and Blood Transfusion / Hämatologie und Bluttransfusion, 515–20. Berlin, Heidelberg: Springer Berlin Heidelberg, 1998. http://dx.doi.org/10.1007/978-3-642-71960-8_68.

Texto completo da fonte

Estilos ABNT, Harvard, Vancouver, APA, etc.

10

Ataullakhanov, Fazoil I., Elena V. Kulikova e Victor M. Vitvitsky. "Binding of Daunorubicin and Doxorubicin to Erythrocytes Treated with Glutaraldehyde". In Erythrocytes as Drug Carriers in Medicine, 143–48. Boston, MA: Springer US, 1997. http://dx.doi.org/10.1007/978-1-4899-0044-9_19.

Texto completo da fonte

Estilos ABNT, Harvard, Vancouver, APA, etc.

Trabalhos de conferências sobre o assunto "Daunorubicin"

1

Sheng, Xia, Jean-Hugues Parmentier, Jonathan Tucci, Hua Pei, Omar Cortez-Toledo, Christina Dieli-Conwright, Matthew Oberley et al. "Abstract 2960: Adipocytes sequester and metabolize daunorubicin". In Proceedings: AACR Annual Meeting 2017; April 1-5, 2017; Washington, DC. American Association for Cancer Research, 2017. http://dx.doi.org/10.1158/1538-7445.am2017-2960.

Texto completo da fonte

Estilos ABNT, Harvard, Vancouver, APA, etc.

2

Rios-Doria, Jonathan, Tara L. Costich, Adam Carie e Kevin Sill. "Abstract 4453: Development of a crosslinked, daunorubicin-loaded micelle with superior pharmacokinetics compared to free daunorubicin and with tunable stability". In Proceedings: AACR 102nd Annual Meeting 2011‐‐ Apr 2‐6, 2011; Orlando, FL. American Association for Cancer Research, 2011. http://dx.doi.org/10.1158/1538-7445.am2011-4453.

Texto completo da fonte

Estilos ABNT, Harvard, Vancouver, APA, etc.

3

Osdal, Tereza, Lars P. Jordheim, Mihaela Popa, Lene M. Vikebø, Andre Sulen, Siv Lise Bedringaas, Marit Liland Sandvold et al. "Abstract 3274: Combination of elacytarabine and daunorubicin is significantly more effective than combination of cytarabine and daunorubicin in primary patient xenografts of AML." In Proceedings: AACR 104th Annual Meeting 2013; Apr 6-10, 2013; Washington, DC. American Association for Cancer Research, 2013. http://dx.doi.org/10.1158/1538-7445.am2013-3274.

Texto completo da fonte

Estilos ABNT, Harvard, Vancouver, APA, etc.

4

Sheng, Xia, Jonathan Tucci, James Behan e Steven D. Mittelman. "Abstract 172: Adipocytes decrease daunorubicin concentration in acute lymphoblastic leukemia cells". In Proceedings: AACR Annual Meeting 2014; April 5-9, 2014; San Diego, CA. American Association for Cancer Research, 2014. http://dx.doi.org/10.1158/1538-7445.am2014-172.

Texto completo da fonte

Estilos ABNT, Harvard, Vancouver, APA, etc.

5

Parmentier, Jean-Hugues, Christina M. Dieli-Conwright e Steven D. Mittelman. "Abstract 3185: Adipocyte-derived hydrogen peroxide promotes chemoresistance to daunorubicin in leukemia cells". In Proceedings: AACR Annual Meeting 2017; April 1-5, 2017; Washington, DC. American Association for Cancer Research, 2017. http://dx.doi.org/10.1158/1538-7445.am2017-3185.

Texto completo da fonte

Estilos ABNT, Harvard, Vancouver, APA, etc.

6

Sheng, Xia, Jonathan Tucci e Steven D. Mittelman. "Abstract 1247: Reduction of oxidative stress promotes daunorubicin resistance in acute lymphoblastic leukemia cells". In Proceedings: AACR 106th Annual Meeting 2015; April 18-22, 2015; Philadelphia, PA. American Association for Cancer Research, 2015. http://dx.doi.org/10.1158/1538-7445.am2015-1247.

Texto completo da fonte

Estilos ABNT, Harvard, Vancouver, APA, etc.

7

Costich, Tara Lee, Rick Crouse, Adam Carie, Taylor Buley, Tyler Ellis, Lauren Repp, J. Edward Semple, Tomas Vojkovsky, Suzanne Bakewell e Kevin Sill. "Abstract 1317: IT-143: A nanoparticle delivery platform that encapsulates daunorubicin and widens therapeutic window". In Proceedings: AACR 107th Annual Meeting 2016; April 16-20, 2016; New Orleans, LA. American Association for Cancer Research, 2016. http://dx.doi.org/10.1158/1538-7445.am2016-1317.

Texto completo da fonte

Estilos ABNT, Harvard, Vancouver, APA, etc.

8

Contente, Thais C., Iara F. Kretzer, Durvanei A. Maria, Tathiana Capeto, Ricardo Fock e Raul C. Maranhao. "Abstract 2656: Association of daunorubicin to a lipidic nanoemulsion (NEM-ODNR) - in vivo tumor growth inhibition". In Proceedings: AACR 101st Annual Meeting 2010‐‐ Apr 17‐21, 2010; Washington, DC. American Association for Cancer Research, 2010. http://dx.doi.org/10.1158/1538-7445.am10-2656.

Texto completo da fonte

Estilos ABNT, Harvard, Vancouver, APA, etc.

9

Lin, Tara L., John M. Perry, Xi He, Gregory Reed, Na Zhang, Scott Weir, Joseph McGuirk e Linheng Li. "Abstract CT103: Low-dose daunorubicin to target leukemia stem cells in newly diagnosed and relapsed/refractory AML". In Proceedings: AACR Annual Meeting 2019; March 29-April 3, 2019; Atlanta, GA. American Association for Cancer Research, 2019. http://dx.doi.org/10.1158/1538-7445.sabcs18-ct103.

Texto completo da fonte

Estilos ABNT, Harvard, Vancouver, APA, etc.

10

Jelinkova, Ludmila, e Yuichiro Suzuki. "Effects Of Daunorubicin On Pulmonary Artery Smooth Muscle Cells In Rat Model Of Hypoxia-Induced Pulmonary Hypertension". In American Thoracic Society 2010 International Conference, May 14-19, 2010 • New Orleans. American Thoracic Society, 2010. http://dx.doi.org/10.1164/ajrccm-conference.2010.181.1_meetingabstracts.a1181.

Texto completo da fonte

Estilos ABNT, Harvard, Vancouver, APA, etc.

Oferecemos descontos em todos os planos premium para autores cujas obras estão incluídas em seleções literárias temáticas. Contate-nos para obter um código promocional único!